Introduction
Human gene therapy trials targeting lung disease have mainly focused on lung cancer, mesothelioma and cystic fibrosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Results from these protocols have successfully demonstrated that human gene transfer is possible, and that transferred gene expression could be at sufficiently high levels to evoke biological responses which cure or control disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] These results provide a theoretical basis for the feasibility of human gene therapy, suggesting broader applications for gene transfer in other common disorders such as lung injury, pulmonary fibrosis, chronic pulmonary airway diseases and asthma. [12] [13] [14] Among lung disorders, acute lung injury (ALI) is caused by many conditions including sepsis, multiple trauma, and pancreatitis, leading to the generalized intravascular activation of inflammatory cells and endothelial or parenchymal cell injury. 15 As inflammatory responses are characterized by high levels of pro-inflammatory cytokines, strategies to antagonize their function or to enhance the effects of anti-inflammatory cytokines have been developed. 16 For example, the overexpression of the soluble tumor necrosis factor (TNF)-␣ receptor by an adenovirus vector (Ad) effectively protected mice from lipopolysaccharide (LPS)-induced sepsis. 17 The use of antisense oligonucleotides against pro-inflammatory cytokines, or adhesion molecules important in the development of inflammation (interleukin (IL)-1, IL-1 receptor, TNF-␣, ICAM-1) have also been successful in vivo. [18] [19] [20] Another strategy to protect lung tissue is based on the fact that high levels of toxic, reactive oxygen species are present in the local milieu where acute inflammation is ongoing. In this regard, the transfer of prostaglandin G/H synthase gene has been effective in an experimental model. 21 Studies on specific signal transduction pathways downstream to cytokine receptors provide wider applications of gene therapy targeting lung injury. For example, a recently identified, mitogen-activated protein kinase (p38MAPK) is activated in cells stimulated with LPS, TNF-␣, UV radiation, hydrogen peroxide, and cell wall components from gram-positive bacteriae. P38MAPK is required for activation of a heat shock protein or in the up-regulation of inflammatory cytokines, thus suggesting its essential role in regulating various acute or chronic host inflammatory responses. [22] [23] [24] Among the heat shock proteins, heme oxygenase-1 (HO-1) is an inducible heat shock protein that oxidatively degrades heme to biliverdin. Biliverdin is rapidly reduced to bilirubin, which, together with another endproduct, ferritin, protects cells from a variety of oxidative stresses such as ultraviolet A, hydrogen peroxide or LPS. 25, 26 A by-product of the HO-1 enzymatic reaction, carbon monoxide (CO), is a recently recognized gaseous mediator. 27 CO has been demonstrated to raise intracellular cyclic GMP levels, prevent apoptosis, and downregulate proinflammatory cytokine expression by modulating the p38MAPK activity in vitro. [28] [29] [30] The pharmacological upregulation of endogenous HO-1 has been shown to resolve acute inflammatory reactions in experimental models by increasing survival rate of animals under LPSinduced shock, and attenuating neutrophil migration into the pleural cavity following carragenin injection. 31, 32 It has also been demonstrated that overexpression of exogenously inserted HO-1 cDNA in gene transfer vectors confer therapeutic benefit on a murine model of hyperoxia 33 or LPS induced lung injury. 34 These experimental results demonstrated by using relatively simple proinflammatory stimuli (LPS, hyperoxia, hydrogen peroxide, TNF-␣) are consistent with the concept that HO-1 overexpression has the ability to attenuate lung injury induced by a variety of airborne pathogens by modulating cytokines expression profiles via a change in the p38MAPK activity, by decreasing inflammatory cell migrations into the lung, or by suppressing apoptotic deaths of respiratory epithelial cells induced by reactive oxygen species.
In the present study, we reasoned that HO-1 gene transfer and overexpression by a replication-deficient adenovirus vector containing rat HO-1 cDNA (Ad.HO-1) would provide therapeutic benefit on a severe lung injury model induced by a type A influenza virus (H1N1). The data demonstrate that pre-administration of Ad.HO-1 attenuated migration of inflammatory cells in the lung following H1N1 inoculation, decreased pathological changes and increased the survival of test animals. Further analysis showed that Ad.HO-1 administration not only significantly down-modulated proinflammatory cytokine production evoked by the administration of Ad vector particles, but also attenuated the DNA fragmentation of respiratory epithelial cells and activation of the caspase pathway induced by H1N1. These suggest that exogenous HO-1 gene transfer could be a potential therapeutic approach to treat acute lung injury induced by viruses or other microorganisms such as bacteriae and Pneumocystis carinii.
Results
Pathology of the lung Consistent with previous reports, 35 intranasal administration of H1N1 (1.7 × 10 4 p.f.u.; plaque forming units) to 6-week-old BALB/c mice resulted in marked peribronchial and perivascular infiltration of inflammatory cells, thickening of alveolar septa and exudation into airspace at 7 days after viral inoculation (Figure 1b) . In animals pretreated with a control Ad containing an empty expression cassette, Ad.null (5 × 10 8 p.f.u.), the magnitude of inflammation was essentially similar to that observed with H1N1 administration alone (Figure 1c ). In contrast, animals pretreated with Ad.HO-1 inoculation (5 × 10 8 p.f.u.) showed a marked suppression of inflammatory changes in the lung (Figure 1d ). As expected, no inflammatory cells were found in the lung of naive controls (Figure 1a) . 
Bronchoalveolar lavage (BAL)
To quantitatively evaluate the effect of Ad.HO-1 in attenuating inflammation in the lung following H1N1, BAL was performed 7 and 14 days after H1N1 administration. At day 7 after H1N1 inoculation, the number of total cells in the BAL fluid (BALF) was markedly increased (H1N1 versus naive, P Ͻ 0.01, Figure 2a) . Pretreatment with Ad.null did not affect the number of total cells compared with animals receiving H1N1 alone. In contrast, pretreatment with Ad.HO-1 resulted in a significant reduction in total cell count (Ad.HO-1 plus H1N1 versus Ad.null plus H1N1 or H1N1, both P Ͻ 0.01). Analysis of cellular components in the BALF revealed that administration of H1N1 alone resulted in a marked increase in macrophages (H1N1 versus naive, P Ͻ 0.01) and neutrophils (H1N1 versus naive, P Ͻ 0.01) (Figure 2b and c) . Pretreatment with Ad.null before H1N1 inoculation also resulted in a similar, marked increase in macrophages and neutrophils. In contrast, pretreatment with Ad.HO-1 showed significant reduction in both macrophages and neutrophils compared with H1N1 inoculation alone or Ad.null plus H1N1 (H1N1 versus Ad.HO-1 plus H1N1 or Ad.null plus H1N1, both P Ͻ 0.01) (Figure 2b and c). In contrast to the marked increase in the number of lymphocytes following H1N1 (naive versus H1N1, P Ͻ 0.01), preadministration of Ad.null or Ad.HO-1 were equally effective in reducing lymphocytic migration into the lung ( Figure  2d ).
Evaluation of cytokine concentration in the BALF was performed by ELISA on samples collected at 7 days after H1N1 inoculation. Concentrations of TNF-␣ in the BALF were lowest in naive animals. Administration of H1N1 alone resulted in their significant elevation, and pretreatment with Ad.null resulted in a marked, further increase in TNF-␣ (H1N1 versus Ad.null plus H1N1, P Ͻ 0.05). Pretreatment with Ad.HO-1 significantly decreased the TNF-␣ levels compared with animals treated with Ad.null plus H1N1, but that was still at a similar level to the animals receiving H1N1 alone (Ad.null plus H1N1 versus Ad.HO plus H1N1, P Ͻ 0.01, Figure 3a ). Interferon-␥ (IFN-␥) levels in the BALF of naive animals were also the lowest observed in this study. Administration of Gene Therapy H1N1 alone and treatment with Ad.null plus H1N1 resulted in a marked elevation (naive versus H1N1 or Ad.null plus H1N1, both P Ͻ 0.05). Treatment with Ad.HO-1 plus H1N1 also resulted in an elevation of IFN-␥ levels above baseline that were similar to those found both in Ad.null plus H1N1 as well as H1N1 administration alone (Figure 3b ). IL-1␤ levels in the BALF of animals infected with H1N1 were significantly higher than the naive animals, but pretreatment with Ad.null further upregulated the IL-1␤ expression (H1N1 versus Ad.null plus H1N1, P Ͻ 0.05). Interestingly, IL-1␤ levels in the BALF of animals pretreated with Ad.HO-1 were significantly decreased compared with those from animals infected with Ad.null plus H1N1 (Ad.null plus H1N1 versus Ad.HO-1 plus H1N1, P Ͻ 0.01, Figure 3c ).
Effect of HO-1 overexpression on survival rate
To demonstrate the therapeutic potential of HO-1 gene transfer on influenza virus-induced lung injury in animals, we compared the survival rate of animals after H1N1 inoculation with or without the preadministration of Ad.HO-1 or Ad.null. Ten mice were used for each group. In contrast to other experiments performed in the present study, 5-week-old BALB/c mice (18-20 g body weight) were treated with the same dose of H1N1 (1.7 × 10 4 p.f.u.) which increased the relative viral dose to their body weight, producing a severe fatal lung injury model. All of the animals inoculated with H1N1 alone died by day 10. Pretreatment with Ad.null did not affect the survival rate of animals following H1N1 infection. In marked contrast, administration of Ad.HO-1 reduced the lethal effect of H1N1, in that 60% of the animals were alive at day 21 (Ad.HO-1 plus H1N1 versus H1N1 or Ad.null plus H1N1, both P Ͻ 0.005, Figure 4 ).
Elimination of H1N1 from the lung
Based on the hypothesis that the therapeutic effect of HO-1 on H1N1-induced lung injury may depend on the ability of HO-1 to influence H1N1 virus replication and clearance from the lung, we quantified the amount of H1N1 in the lungs of infected mice with or without pretreatment with Ad.Ho-1 or Ad.null. Consistent with previous reports, 36 inoculation with H1N1 resulted in pulmonary infection with a robust increase in viral titer, peaking at day 7, but undetectable at day 14 ( Figure 5 ). Interestingly, there was no difference in the amount of H1N1 detected in the lung between animals receiving either Ad.null or Ad.HO-1 pre-administration and H1N1 alone at any of the time points studied ( Figure 5 ).
Effect of Ad.HO-1 on DNA fragmentation induced by H1N1
To examine the mechanism involved in HO-1-mediated protection of the lung against H1N1 infection, the effect of HO-1 gene expression on respiratory epithelial cell damage following H1N1 infection was evaluated. To 
Effect of Ad.HO-1 on caspase activation induced by H1N1
To further understand the protective mechanism employed by HO-1 in H1N1-induced lung injury, we analyzed the lungs of animals for caspase activity. Infection with H1N1 alone resulted in a three-fold increase in the activity of caspase-8. Administration of Ad.null before the H1N1 infection somewhat down-modulated the increase in caspase-8 activity. However, only pretreatment with Ad.HO-1 decreased caspase-8 activity to a statistically significant level (H1N1 versus Ad.HO-1 plus H1N1, P Ͻ 0.05, Figure 8a ). In contrast, infection with H1N1 increased caspase-3 activity by two-fold ( Figure  8b ), which was not affected by pretreatment with either Ad.null or Ad.HO-1 following H1N1 infection, suggesting caspase-3 activity was not affected by HO-1 overexpression (Figure 8b ). 25,26,37 HO-1 is the rate-limiting enzyme in heme degradation, but recent reports have emphasized the importance of HO-1 in modulating the magnitude of inflammation. 32, 38 The potential of bilirubin and ferritin, endproducts of HO-1-mediated reactions to protect cells from oxidative stress has been demonstrated in vitro. 39, 40 Similarly, CO, a by-product of HO-1-mediated heme degradation, has been shown in vitro to stimulate p38 MAPK, a molecule pivotal in the expression of various cytokines. [22] [23] [24] 30 In this regard, Otterbein et al 28, 30 have demonstrated that macrophages cultured in air containing CO showed an increase in IL-10, as well as a decrease in TNF-␣ and IL-1␤ production. Consistent with this observation, neutrophil migration into the lung following an intratracheal challenge of LPS was attenuated when animals breathed air containing CO, but that was not attenuated in animals lacking p38 MAPK. 28 , 30 Inoue et al 34 have also demonstrated that neutrophil migration to the lung following LPS inhalation was markedly attenuated by pre-administration of an endogenous HO-1 inducer, hemin, or an Ad expressing HO-1 in mice, and further demonstrated that IL-10 overproduction by macrophages was essential for suppressed neutrophilic inflammation. Together, these data suggest that overexpression of HO-1 results in CO production, which modifies cytokine profiles within both inflammatory and respiratory epithelial cells, thus suppressing neutrophil migration into the lung in response to LPS. In this regard, the present study demonstrated that pre-administration of Ad.HO-1 not only decreased the number of inflammatory cells in the lung following influenza virus inoculation, but also enhanced survival rates. In addition to previous reports where lung injury models using simplified stimuli such as LPS, hyperoxia or carragenin were examined, 31-33 our study demonstrates for the first time the potential of HO-1 gene transfer to treat lung injury caused by an inhaled pathogen commonly seen in humans.
Figure 8 Caspase activity in test animal lungs after H1N1 inoculation. Activity of caspase-8 (a) and caspase-3 (b) were determined by using
Our analysis of BAL fluid herein revealed that the number of total cells, macrophages and neutrophils were all decreased in animals treated with Ad.HO-1 followed by H1N1, which is consistent with the theory that HO-1 is involved in the resolution of lung inflammation. [31] [32] [33] Similar decreases in macrophages and neutrophils have been reported in animals using hyperoxia or LPS as inducers of inflammation. In contrast to previous reports showing that IL-10 expression was enhanced in animals receiving either an HO-1 expression vector or CO, our preliminary experiments showed that IL-10 in BALF was not elevated by Ad.HO-1 pretreatment. Measurement of IL-1␤ in the BALF, however suggest that Ad-mediated HO-1 gene expression significantly suppressed proinflammatory cytokine production in response to Ad particles, but their levels remained high compared with naive animals. Together, these findings suggest that the modulated expression of pro-or anti-inflammatory cytokines is not the only mechanism to explain down-modulation of inflammatory reactions and enhanced survival of animals following H1N1 inoculation.
Administration of the influenza virus not only results in the innate immune reaction of macrophages and neutrophils, but also evokes lymphocytic infiltration including class I-restricted, cytotoxic T lymphocytes (CTL). 41 Our data demonstrated that pre-administration of Ad vector particles (Ad.null) significantly reduced the number of lymphocytes in the lung. However, as Ad.null administration alone was not sufficient to prevent pulmonary hemorrhage (data not shown), or to increase the survival rate of test animals (Figure 4) , a decrease in lymphocytes in the lung in response to Ad.null is unlikely to confer significant therapeutic benefit in this lung injury model. Further experiments are required to understand how HO-1 is involved in the development of lymphocytic inflammation. Importantly, the rates of influenza virus elimination were identical in animals receiving Ad.null, Ad.HO-1, and influenza virus alone, indicating that the adoptive immune response to the virus is not modulated by HO-1 overexpression ( Figure 5 ).
Despite the survival of all animals studied, administration of the influenza virus with or without Ad.null resulted in massive pulmonary hemorrhage and consolidation mimicking the characteristics of acute lung injury (Figures 1) . 15, 31 Based on the knowledge that overexpression of HO-1 prevents cell death from a variety of stresses including hyperoxia, exposure to heme, hydrogen peroxide or LPS, we performed TUNEL analysis to detect DNA fragmentation in lung cells as a measure of cell damage. 31, 42, 43 Consistent with previous findings that influenza virus inoculation results in severe apoptosis of respiratory epithelium, inoculation with H1N1 in our study resulted in a marked increase in the number of respiratory epithelial cells and inflammatory cells with damaged DNA. [44] [45] [46] In contrast, animals receiving pretreatment of Ad.HO-1 demonstrated marked reduction in cells positive for DNA damage, thus preventing injury.
To date, death receptor-dependent pathways mediated by TNF and Fas, as well as receptor-independent, mitochondrial-mediated apoptotic pathways evoked by stimuli such as anti-cancer drugs, radiation, and reactive oxygen species have been identified. 47 Fujimoto and coworkers 48 showed that influenza infection induces apoptosis via activation of pathways mediated by the Fas-Fas ligand complex in Hela cells. Fas and Fas ligand then activate a caspase cascade and induce apoptosis. Caspase-8 is located downstream to both TNF-receptor 1 (TNFR) and Fas. 47 Death signaling through these receptors is transduced via interaction of their death domains (DD) with the TNFR-associated death domain protein (TRADD) or Fas-associated death domain protein (FADD). In contrast, caspase-3 activation is elicited by both DD and death receptor-independent stimuli. 47 It has been demonstrated that in murine 3T3 L1 cells, influenza virus infection results in a three-fold increase in caspase-8 activity above control levels, but does not influence caspase-9. This suggests that apoptosis induced by the influenza infection mainly depends on the activity of caspase-8. 49 The present study demonstrated that caspase-8 activity in the lungs of animals pretreated with Ad.HO-1 was similar to that of naive animals, which was associated with increased survival. In contrast, Ad.HO-1 overexpression did not affect caspase-3 activity, suggesting that modulation of caspase-8 activity is essential in protecting cells infected with influenza virus. Previous reports demonstrate that CO, the by-product of HO-1, inhibited apoptosis in endothelial cells by modulating p38MAPK activity. 50 Otterbein et al 33 have also demonstrated that Ad-mediated Ho-1 cDNA overexpression inhibited apoptosis and death of rats bred under hyperoxia. Our findings that HO-1 overexpression inhibited caspase activation are consistent with these reports.
Our data suggest that the administration of Ad.null slightly decreased the number of damaged cells despite a high level of TNF-␣ expression in the lung. Several reports demonstrate that the presence of activated NF-B within cells provides an inhibitory effect on apoptotic cell death induced by TNF. 51, 52 Hida and coworkers 53 also demonstrated that a potent NF-B inhibitor induced apoptosis through activation of caspase-3 and caspase-8. As the pretreatment of animals with Ad.null is known not only to induce high levels of TNF-␣, but to also activate NF-B, this NF-B activation may be partly responsible for the prevention of TNF-induced lung injury. However, the effects of Ad.null administration herein were not sufficient to decrease the magnitude of pulmonary hemorrhage or the subsequent death of test animals.
In summary, the present study demonstrates for the first time the ability of adenovirus-mediated overexpression of HO-1 cDNA in the lung to prevent the death of animals infected with the influenza virus. Ad.HO-1 was shown to act through the inhibition of the death signaling pathway mediated by, at least in part, caspase-8 activation. By using the influenza virus, an inhaled pathogen commonly seen in the clinical setting, our data further support the use of exogenous HO-1 overexpression for the effective treatment of acute lung injury in human gene therapy applications.
Materials and methods

Influenza virus
Influenza virus A/PR8/34 (H1N1) was used in the present study to develop a severe lung injury model. 54 The virus was grown in Mardin-Darby canine (MDCK) cells cultured in Eagle's minimal essential medium (MEM), containing 10% fetal bovine serum (FBS) for 2 days, after which viruses were collected and stored −80°C. The virus titer was quantitated by plaque assay as described. 55 
Adenovirus vectors
Replication-deficient adenovirus vectors containing rat HO-1 cDNA (Ad.HO-1) were generated in HEK293 cells grown in Dulbecco's modified Eagle medium (DMEM), containing 10% FBS by homologous recombination of a plasmid pCMV.HO-1 and pJM17, a circularized adenovirus genome with its E1 and a portion of E3 regions deleted.
56,57 pCMV.HO-1 was constructed by inserting the full length of rat HO-1 cDNA (kindly provided by Dr S Shibahara, Tohoku University, Sendai, Japan) into the cloning site of pCMV-SV 2+ (a generous gift from Ronald G Crystal, Cornell-Medical College, New York, NY, USA). 58, 59 HO-1 cDNA expression was controlled by the cytomegalovirus immediate -early promoter/enhancer. The generated virus, Ad.HO-1 was propagated in HEK293 cells, and purified by cesium chloride gradient ultra centrifugation. Virus was titered on HEK293 cells, and stored at −80°C. Ad.null, a control vector, was generated by the homologous recombination of a shuttle plas-mid containing no expression cassette, p⌬sp1A (Microbix, Ontario, Canada) and the pJM17.
Experimental protocols
Balb/c mice (Japan SLC, Shizuoka, Japan) were treated with intranasal inoculation of the H1N1 (1.7 × 10 4 p.f.u., total volume, 30 l) under light anesthesia with inhaled diethyl ether. To evaluate the therapeutic effects of HO-1 gene transfer, Ad.HO-1 or Ad.null was intranasally administered 48 h before the H1N1 (5 × 10 8 p.f.u., total volume 30 l) under light anesthesia with diethyl ether. In our preliminary experiments using LPS aerosols as an inducer of neutrophilic inflammation, Ad.HO-1 suppressed neutrophil migration in a dose-dependent manner up to 1 × 10 9 p.f.u. However, as intranasal inoculation of the adenovirus solution in volumes greater than 50 l often resulted in suffocation of test animals, we used half of the maximum viral dose (5 × 10 8 p.f.u.) throughout. Based on another preliminary experiment showing that inoculation of the same dose of H1N1 (1.7 × 10 4 p.f.u.) resulted in 100% death of 5-week-old Balb/c (18-20 g body weight) within 10 days due to severe pneumonia, 5-week-old Balb/c were used to evaluate the ability of HO-1 gene transfer to increase the survival rate ( Figure  4) . In all other experiments where histopathological and quantitative analysis by lung lavage were performed, 6-week-old mice (23-24 g body weight) were used to decrease viral burden, so that all animals survived with the same dose of H1N1, without HO-1 gene transfer.
Bronchoalveolar lavage (BAL)
To quantitatively analyze host response to the H1N1 or Ad-mediated HO-1 gene transfer, lung lavage was performed 7 and 14 days after H1N1 inoculation. Animals were deeply anesthetized with an intraperitoneal injection of sodium pentobarbital, and a cannula was inserted into the trachea. Cells were collected by lung lavage with phosphate-buffered saline (PBS, 0.8 ml), which was repeated three additional times. Samples were centrifuged (1000 g 10 min) and the supernatant was stored at −80°C for cytokine analysis. Cells were resuspended in PBS, counted and Diff-Quick stained (International Reagents, Kobe, Japan). Concentrations of TNF-␣, IFN-␥ and IL-1␤ in the BAL fluid at day 7 were determined by sandwich enzyme linked immunosorbent assay (ELISA) following instructions provided by the manufacturer (R& D, Minneapolis, MN, USA). The detection limit of the assay was 0.1 pg/ml.
Histopathological examination
For microscopic evaluation of pathological changes in the lung, animals in each experimental group were killed at 7 days following H1N1. The lung was removed and inflated with 10% formalin in PBS. After fixation, the lung was embedded in paraffin, sectioned, and stained with hematoxylin and eosin.
H1N1 titer in the lung
To evaluate the effect of HO-1 gene transfer on the rate of H1N1 elimination from the lung, lungs were removed at days 1, 7 and 14 after H1N1 infection, and homogenized in 9 ml of PBS. The extracts were centrifuged for 10 min at 1000 g, and the supernatants were diluted serially 10-fold in PBS supplemented with 0.2% bovine serum albumin. Virus yield was quantified by the stanGene Therapy dard plaque-forming assay of virus suspensions in MDCK cells. 55 
TUNEL analysis
As the influenza virus induces apoptosis in the lung, [22] [23] [24] the effect of HO-1 gene transfer on the magnitude of DNA fragmentation was examined by using the terminal deoxynucleotide transferase-mediated dUTP nick endlabeling (TUNEL) method. 60 Histological sections from animals 7 days after H1N1 inoculation were fixed with paraformaldehyde at room temperature and labeled as described by the manufacturer (In Situ Cell Death Detection kit; Boehringer Mannheim, Mannheim, Germany). To quantitatively express the data, 500 respiratory cells were randomly selected and number of positively stained cells were counted, and that was repeated three times in each sample, averaged and reported. Quantification of TUNEL was performed by a pathologist who did not know the experimental protocol of the present study.
Caspase activities
To evaluate the effect of HO-1 overexpression on the apopototic pathway mediated by caspases, caspase-3 and caspase-8 activity in lung homogenates were measured. 61 pNA conjugated to the tetrapeptide Asp-Glu-Val-Asa Asp (DEVD) was used as the substrate to measure caspase-3 while pNA conjugated to the tetrapeptide Ile-GluThr-Asp (IETD) was used to determine caspase-8 activity. Cleavage of these substrates by caspase-3 or caspase-8 releases pNA, which was then measured by absorbance (FLICE/Caspase colorimetric protease assay kit, Medical and Biological Laboratories, Nagoya, Japan 62, 63 ).
Statistics
Data are presented as means ± standard error of the means (s.e.m.). To compare differences in mean values among multiple groups tested, comparison was performed by two-way analysis of variance (ANOVA). A logrank analysis was used to compare survival curves of test animals. A P value Ͻ0.05 was considered statistically significant.
